Scinai regains Nasdaq minimum bid price compliance; shares up
- Scinai Immunotherapeutics (SCNI) has regained compliance with Nasdaq’s $1 minimum bid price requirement.
- Nasdaq has closed the compliance matter, removing the company’s previous minimum-bid-price deficiency.
- SCNI shares up 10.6% premarket.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.